Altimmune (ALT)
(Delayed Data from NSDQ)
$6.46 USD
-0.28 (-4.09%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $6.46 +0.01 (0.08%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Altimmune, Inc. [ALT]
Reports for Purchase
Showing records 41 - 60 ( 75 total )
Company: Altimmune, Inc.
Industry: Medical - Drugs
Healthcare- Three Must Dial-In Calls Next Week:
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Altimmune, Inc.
Industry: Medical - Drugs
Three Must Dial-In Calls Next Week: NASH, Omega-3s, and COVID-19 - MS
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Altimmune, Inc.
Industry: Medical - Drugs
1Q20 - Strike Ahead: The Iron Heats Up in 4Q20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Altimmune, Inc.
Industry: Medical - Drugs
Company: Altimmune, Inc.
Industry: Medical - Drugs
Company: Altimmune, Inc.
Industry: Medical - Drugs
Company: Altimmune, Inc.
Industry: Medical - Drugs
NASH: Impact of Semaglutide GLP-1 NASH Data on NASH Stocks
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Altimmune, Inc.
Industry: Medical - Drugs
Takeaways from Our NASH and GLP-1 Expert Call with Dr. Juan Frias
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Altimmune, Inc.
Industry: Medical - Drugs
Do Not Miss Our GLP-1 Call with Dr. Juan Frias Today at 12pm ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Altimmune, Inc.
Industry: Medical - Drugs
Healthcare Do Not Miss Our GLP-1 Call with Dr. Juan Frias on May 1 at 12pm
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Altimmune, Inc.
Industry: Medical - Drugs
Do Not Miss Our GLP-1 Call with Dr. Juan Frias on May 1 at 12pm ET
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Altimmune, Inc.
Industry: Medical - Drugs
Do Not Miss Part 1 on Monday of Our 4-Part NASH COVID-19 Call Series
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Altimmune, Inc.
Industry: Medical - Drugs
Healthcare- Yas'' Weekly Recap of Our Key Notes and 20 Doc Calls Upcoming in 2Q20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Altimmune, Inc.
Industry: Medical - Drugs
Dial in to Part 2 of Our COVID-19 Drug Developer Call Series Today at 12PM
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Altimmune, Inc.
Industry: Medical - Drugs
Company: Altimmune, Inc.
Industry: Medical - Drugs
Company: Altimmune, Inc.
Industry: Medical - Drugs
Healthcare Dial in to Part 1 of Our COVID-19 Drug Developer Call Series Today at 12PM
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Altimmune, Inc.
Industry: Medical - Drugs
Healthcare - Dial in to Parts 1-2 of Our COVID-19 Drug Developer Series on Apr. 1 - Apr. 2
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y